These Analysts Revise Price Targets On BioNTech After Q4 Results

BioNTech SE BNTX reported a decline in sales for its fourth quarter.

BioNTech reported Q4 FY22 revenues of €4.28 billion, down from €5.5 billion a year ago, due to the changes in the demand for COVID-19 vaccines. The company posted Q4 diluted EPS of €9.26, down from €12.18 a year ago.

BioNTech expects FY23 COVID-19 vaccine revenue of approximately €5 billion compared to €17.1 billion in 2022.

BioNTech shares dropped 3.6% to close at $123.60 on Monday and lost 1% in today’s pre-market trading session.

These analysts made changes to their price targets on BioNTech following the release of results.

• Goldman Sachs lowered the price target on BioNTech from $156 to $140. Goldman Sachs analyst Chris Shibutani maintained a Neutral rating.
• Morgan Stanley cut the price target on BioNTech from $216 to $150. Morgan Stanley analyst Matthew Korn maintained an Equal-Weight rating.
• Canaccord Genuity raised the price target on BioNTech from $191 to $203. Canaccord Genuity analyst Bill Selesky maintained the stock with a Buy rating.

Read More: Around $32M Bet On Southwest Gas? Check Out These 3 Stocks Insiders Are Buying